Literature DB >> 23555181

Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Victoria J Christiansen1, Kenneth W Jackson, Kyung N Lee, Tamyra D Downs, Patrick A McKee.   

Abstract

Fibroblast activation protein (FAP), a membrane prolyl-specific proteinase with both dipeptidase and endopeptidase activities, is overexpressed by reactive stromal fibroblasts during epithelial-derived cancer growth. FAP digests extracellular matrix as tissue is remodeled during cancer expansion and may also promote an immunotolerant tumor microenvironment. Recent studies suggest that nonspecific FAP inhibitors suppress human cancer xenografts in mouse models. Prolyl oligopeptidase (POP), another prolyl-specific serine proteinase, is also elevated in many cancers and may have a regulatory role in angiogenesis promotion. FAP and POP cell-associated activities may be targets for diagnosis and treatment of various cancers, but their accessibilities to highly effective specific inhibitors have not been shown for cells important to cancer growth. Despite their frequent simultaneous expression in many cancers and their overlapping activities toward commonly used substrates, precise, separate measurement of FAP or POP activity has largely been ignored. To distinguish each of the two activities, we synthesized highly specific substrates and inhibitors for FAP or POP based on amino acid sequences surrounding the scissile bonds of their respective putative substrates. We found varying amounts of FAP and POP protein and activities on activated fibroblasts, mesenchymal cells, normal breast cells, and one breast cancer cell line, with some cells exhibiting more POP than FAP activity. Replicating endothelial cells (ECs) expressed POP but not FAP until tubulogenesis began. Targeting FAP-positive cells, especially mesenchymal stem cells and cancer-associated fibroblasts for inactivation or destruction, and inhibiting POP-producing EC may abrogate stromal invasion and angiogenesis simultaneously and thereby diminish cancer growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23555181      PMCID: PMC3612908          DOI: 10.1593/neo.121850

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  55 in total

1.  Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis.

Authors:  Ronald T Aimes; Andries Zijlstra; John D Hooper; Steven M Ogbourne; Mae-Le Sit; Simone Fuchs; David C Gotley; James P Quigley; Toni M Antalis
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

2.  Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.

Authors:  J Niedermeyer; M J Scanlan; P Garin-Chesa; C Daiber; H H Fiebig; L J Old; W J Rettig; A Schnapp
Journal:  Int J Cancer       Date:  1997-05-02       Impact factor: 7.396

Review 3.  On the role of prolyl oligopeptidase in health and disease.

Authors:  J A García-Horsman; P T Männistö; J I Venäläinen
Journal:  Neuropeptides       Date:  2006-12-29       Impact factor: 3.286

Review 4.  Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies.

Authors:  Thomas Kelly; Yan Huang; Avis E Simms; Anna Mazur
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

5.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

Review 6.  The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.

Authors:  Ellen Puré
Journal:  Expert Opin Ther Targets       Date:  2009-08       Impact factor: 6.902

Review 7.  Structure, function and biological relevance of prolyl oligopeptidase.

Authors:  Zoltán Szeltner; László Polgár
Journal:  Curr Protein Pept Sci       Date:  2008-02       Impact factor: 3.272

8.  Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow.

Authors:  Sohyun Bae; Chae Woon Park; Hye Kyung Son; Hye Kyung Ju; Donggi Paik; Choon-Ju Jeon; Gou Young Koh; Jaeseob Kim; Hoeon Kim
Journal:  Br J Haematol       Date:  2008-05-24       Impact factor: 6.998

9.  Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.

Authors:  Kyoko Okada; Wen-Tien Chen; Satoshi Iwasa; Xin Jin; Tetsu Yamane; Akishi Ooi; Masako Mitsumata
Journal:  Oncology       Date:  2003       Impact factor: 2.935

10.  Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.

Authors:  Stefan Bauer; Michael C Jendro; Andreas Wadle; Sascha Kleber; Frank Stenner; Robert Dinser; Anja Reich; Erica Faccin; Stefan Gödde; Harald Dinges; Ulf Müller-Ladner; Christoph Renner
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  15 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 2.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models.

Authors:  D V Tyulkina; V V Pleshkan; I V Alekseenko; M R Kopantseva; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2016-11-06       Impact factor: 0.788

4.  The role of fibroblast activation protein in progression and development of osteosarcoma cells.

Authors:  Liang Zhang; Li Yang; Zi-Wei Xia; Shi-Chang Yang; Wen-Hui Li; Bin Liu; Zi-Qi Yu; Peng-Fei Gong; Ya-Lin Yang; Wei-Zong Sun; Jing Mo; Gui-Shi Li; Tian-Yi Wang; Kai Wang
Journal:  Clin Exp Med       Date:  2019-11-19       Impact factor: 3.984

5.  Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation.

Authors:  Yuchen Zhang; Xingwang Zhang; Hongming Liu; Shaohui Cai; Baojian Wu
Journal:  Int J Nanomedicine       Date:  2015-02-26

6.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

7.  Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs.

Authors:  Fiona M Keane; Tsun-Wen Yao; Stefanie Seelk; Margaret G Gall; Sumaiya Chowdhury; Sarah E Poplawski; Jack H Lai; Youhua Li; Wengen Wu; Penny Farrell; Ana Julia Vieira de Ribeiro; Brenna Osborne; Denise M T Yu; Devanshi Seth; Khairunnessa Rahman; Paul Haber; A Kemal Topaloglu; Chuanmin Wang; Sally Thomson; Annemarie Hennessy; John Prins; Stephen M Twigg; Susan V McLennan; Geoffrey W McCaughan; William W Bachovchin; Mark D Gorrell
Journal:  FEBS Open Bio       Date:  2013-12-08       Impact factor: 2.693

8.  Impact of fibroblast activation protein on osteosarcoma cell lines in vitro.

Authors:  Lixiang Ding; Lin Ye; Jianli Xu; Wen G Jiang
Journal:  Oncol Lett       Date:  2014-01-10       Impact factor: 2.967

9.  Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.

Authors:  Margaret G Gall; Yiqian Chen; Ana Julia Vieira de Ribeiro; Hui Zhang; Charles G Bailey; Derek S Spielman; Denise M T Yu; Mark D Gorrell
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

10.  Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells.

Authors:  Catríona M Dowling; Carmen Herranz Ors; Patrick A Kiely
Journal:  Biosci Rep       Date:  2014-07-29       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.